JP Morgan Chase
SRNE

JP Morgan Chase’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

JP Morgan Chase’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-39,500
Closed -$270K – 6473
2020
Q4 		$270K Sell
39,500
-34,200
-46% -$275K ﹤0.01% 4698
2020
Q3 		$855K Buy
73,700
+34,200
+87% +$313K ﹤0.01% 3727
2020
Q2 		$248K Buy
+39,500
New +$151K ﹤0.01% 4177

Other funds holding SRNE

SW
SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
OAJ
Ogorek Anthony Joseph Williamsville, New York $365M AUM 18.21% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return
CFGS
Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

JP Morgan Chase's SRNE Position: Q2 2023 in Review

JP Morgan Chase sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 1 share.

JP Morgan Chase first reported a position in SRNE in Q4 2013 and held it in 32 quarters. The position peaked at $24.9M in Q2 2021. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

  • JP Morgan Chase reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1 Sorrento Therapeutics, Inc. share in Q2 2023.
  • JP Morgan Chase first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and held it in 32 quarters.
  • JP Morgan Chase's Sorrento Therapeutics, Inc. position peaked at $24.9M in Q2 2021.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.